

## ESC Guidelines recommend renal denervation

for uncontrolled and resistant hypertension patients<sup>1</sup>

### The future of hypertension care is now.

The European Society of Cardiology now includes renal denervation (RDN) as a class IIb recommendation that provides a safe and effective complementary option to control blood pressure.<sup>1</sup>

#### Patient Selection criteria

##### Uncontrolled hypertension

-  With increased CV risk
-  Treated with <3 antihypertensive drugs

##### Resistant hypertension

-  Treated with ≥3 antihypertensive drugs including diuretic

And who have:

- eGFR ≥40 ml/min/1.73m<sup>2</sup>
- Express a preference for RDN in a shared-decision making process

#### Additional recommendations

-  Selection of patients should be done after assessment by a multidisciplinary team.

-  Procedure should be performed in experienced medium to high volume centers.

[Read the ESC guidelines](#)

Elevate hypertension care options as you know them.

The Symplicity™ blood pressure procedure delivers **significant, safe, and sustained blood pressure reductions.**<sup>2-6</sup>

Explore the evidence

#### References:

1. McEvoy JW, et al, European Heart Journal, ehae178, <https://doi.org/10.1093/eurheartj/ehae178>
2. Böhm M, et al. Lancet. 2020;395:1444-1451.
3. Kandzari DE, et al. J Am Coll Cardiol. 2023;82:1809-1823.
4. Mahfoud F, et al. Lancet. 2022;399:1401-1410.
5. Mahfoud F, et al. EuroPCR 2023.
6. Mahfoud F, et al. Hypertension. 2023;80:1759-1770.

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).

Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI.

If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website [manuals.medtronic.com](https://manuals.medtronic.com). Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative and/or consult Medtronic's websites.

2024-esc-2024-one-pager-summary-en-gb-emea-14240073 ©2024 Medtronic. Medtronic logo and Engineering the extraordinary are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan, or France.

## Medtronic

#### Europe

Medtronic International Trading Sàrl.  
Route du Molliou 31  
Case postale  
CH-1131 Tolochenaz  
[www.medtronic.eu](https://www.medtronic.eu)  
Tel: +41 (0)21 802 70 00  
Fax: +41 (0)21 802 79 00

#### United Kingdom/Ireland

Medtronic Limited  
Building 9  
Croxley Park  
Hatters Lane  
Watford  
Herts WD18 8WW  
[www.medtronic.co.uk](https://www.medtronic.co.uk)  
Tel: +44 (0)1923 212213  
Fax: +44 (0)1923 241004

© Medtronic 2024.  
All rights reserved.



>9

mmHg

reduction in OSBP in patients off and on medications<sup>2,3</sup>

